scispace - formally typeset
M

Michael R. Shurin

Researcher at University of Pittsburgh

Publications -  203
Citations -  9478

Michael R. Shurin is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Dendritic cell & Immune system. The author has an hindex of 54, co-authored 203 publications receiving 8228 citations. Previous affiliations of Michael R. Shurin include Boston Children's Hospital.

Papers
More filters
Journal ArticleDOI

Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic-pituitary-adrenal axis

TL;DR: It is confirmed by showing that rats exposed to electric footshock, physical restraint, or a conditioned aversive stimulus have increased levels of plasma IL-6, and the kinetics of the increase resembled that of increase in plasma corticosterone, which suggests that increased plasmaIL-6 may be part of the hormonal responses to stress.
Journal ArticleDOI

Dendritic cells in the cancer microenvironment.

TL;DR: Better understanding of DC immunobiology in cancer is pivotal for designing novel or improved therapeutic approaches that will allow proper functioning of DCs in patients with cancer.
Journal ArticleDOI

Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation

TL;DR: Microenvironmental IL-1β is defined as a master cytokine in tumor progression using a model of orthotopically introduced 4T1 breast cancer cells and the combination of anti–IL-1 β plus anti–PD-1 abrogated the tumors completely.
Journal Article

Neuroblastoma-derived Gangliosides Inhibit Dendritic Cell Generation and Function

TL;DR: It is demonstrated that NB-derived gangliosides inhibit the generation of functionally active DCs and may play a role in tumor-induced immunosuppression and subsequent tumor escape from immune recognition and elimination.
Journal ArticleDOI

Th1/Th2 balance in cancer, transplantation and pregnancy.

TL;DR: Successful interventions to regulate Thl/Th2 balance and modify the immune response may decrease the risk of development or relapse of malignancy, avoid impairment of donor cell engraftment, and allow successful fetal maturation.